Faron Pharmaceuticals Oy (LON:FARN) Stock Price Down 4.1% - What's Next?

Key Points

• Faron Pharmaceuticals Oy shares dropped by 4.1% on Tuesday, trading between GBX 170 ($2.27) and GBX 175 ($2.34), with an increase in trading volume to 53,678 shares.
• The company's debt-to-equity ratio stands at 922.55, with a market capitalization of £195.92 million and a P/E ratio of -6.48.
• Faron is focused on developing novel treatments for significant unmet medical needs, particularly through its investigational immunotherapy, Clevegen, targeting immunological responses in various conditions.

Shares of Faron Pharmaceuticals Oy (LON:FARN - ) fell 4.1% on Tuesday . The stock traded as low as GBX 170 ($2.27) and last traded at GBX 175 ($2.34). 53,678 shares traded hands during mid-day trading, an increase of 44% from the average session volume of 37,353 shares. The stock had previously closed at GBX 182.50 ($2.44).

Faron Pharmaceuticals Oy Stock Performance

The company has a quick ratio of 1.09, a current ratio of 1.45 and a debt-to-equity ratio of 922.55. The company's 50-day moving average is GBX 193.99 and its two-hundred day moving average is GBX 206.78. The company has a market capitalization of £195.92 million, a P/E ratio of -6.48 and a beta of 0.36.

About Faron Pharmaceuticals Oy

Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.